And then on June 25, the grocery behemoth (which includes regional chains like King Soopers, Fred Meyer, Ralphs, and Pick’n Save) launched its first-ever sonic identity. There’s a succinct sonic logo ...

The overhaul was nicknamed Project Arden as a nod to the Elizabeth Arden beauty salon, best known at the time for its ...

Developed by Belgian software developer Stijn Spanhove, this prototype app is designed to detect and block real-world ads in ...

ESTEVE has entered into an agreement with Sanofi to acquire Caprelsa® (vandetanib) rights in more than 50 countries, a treatment that is ...

Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other ...

Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its early-stage neurology pipeline.

In response to the antivaccine movement in the U.S., CEOs from GSK and Sanofi stressed the need for transparency in discussing the value of vaccines.

Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top 10 drugs in global sales — early next year. It’s unclear how ...

Sanofi is buying Inhibrx in a $1.7 billion deal as the French pharmaceutical giant expands its pipeline of drugs that can treat rare diseases.

Sanofi says that it is currently developing 12 experimental medicines it believes could generate annual sales of $2 billion or more. Will investors believe it?

Sanofi's move from Bridgewater to Morris will take place in two phases in the fourth quarter of 2024 and first quarter of 2025, a statement from said.

The research collaboration comes on the heels of several other high-value AI drug discovery partnership announcements from Sanofi.